solute carrier family 12 member 4Genealiases: CTC-479C5.17 · KCC1 · hKCC1
Q-omics provides the consensus-scored SLC12A4 profile across patient tissues and cancer cell-line models. SLC12A4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SLC12A4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SLC12A4 protein abundance shows 21,035 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, HNSC, and LSCC as cancer lineages where SLC12A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC12A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC12A4 survival associations across molecular data types. SLC12A4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC12A4 RNA expression–survival associations across cancer types. High SLC12A4 expression shows unfavorable associations in LUSC, ACC and HNSC, but favorable associations in KIRC, KIRP and THYM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SLC12A4 RNA expression.
This table summarizes SLC12A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC12A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC12A4 shows lower tumor expression in LUAD and higher tumor expression in HNSC, KIRC, LIHC, COAD and KIRP. The HNSC box plot shows higher SLC12A4 RNA expression in tumor versus normal tissue (log2 FC = +1.296, t-test p < 0.001).
This table shows molecular features associated with SLC12A4 in patient tissues and cancer cell lines. In patient samples, SLC12A4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC12A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
